Biogen (BIIB) Acquisitions (2010 - 2023)

Biogen (BIIB) posted quarterly Acquisitions of $590.5 million for Q4 2023, up 197.03% quarter-over-quarter from $198.8 million in Q1 2015.

Biogen (BIIB) Acquisitions (2010 - 2023) Analysis & Trends

Biogen's Acquisitions history runs 5 years deep, the most recent figure standing at $590.5 million for Q4 2023.

In Q4 2023, Acquisitions changed N/A year-over-year to $590.5 million; the TTM figure through Dec 2025 stood at $590.5 million (changed 0.0% YoY), while the FY2024 annual figure was $1.1 billion, down 84.48% from the prior year.
Acquisitions for Q4 2023 stood at $590.5 million, up from $198.8 million in the prior quarter.
The five-year high for Acquisitions was $590.5 million in Q4 2023, with the low at $590.5 million in Q4 2023.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	Acquisitions (Qtr)
1	Johnson & Johnson	653.75 Bn	633.00 Bn	17.26 Bn	-17.24 Bn
2	AbbVie	470.62 Bn	464.05 Bn	12.70 Bn	-
3	Merck	376.18 Bn	369.04 Bn	12.21 Bn	-
4	Novartis Ag	303.75 Bn	296.06 Bn	11.24 Bn	-
5	Astrazeneca	257.67 Bn	252.77 Bn	12.86 Bn	-
6	Amgen	236.39 Bn	222.40 Bn	7.24 Bn	-
7	Gilead Sciences	182.04 Bn	178.86 Bn	6.22 Bn	11.21 Bn
8	Pfizer	159.49 Bn	147.79 Bn	10.94 Bn	-
9	Gsk	106.27 Bn	102.10 Bn	8.24 Bn	-
10	Biogen	32.05 Bn	30.77 Bn	1.96 Bn	-

Download Data